BINEX Co., Ltd.
Financials
Valuation Metrics
BINEX Co., Ltd.'s Market Cap is ₩1958B. At end of 2025 it was ₩4896B. Ranked #814 of 2,405 in KR market (top 34%), #367 of 1,627 on KOSDAQ (top 23%), #89 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 39%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 195.78B KRW | KR#814/2,405 Sec#89/231 |
| Revenue | 157.28B KRW | KR#1,148/2,405 Sec#70/231 |
| Net Income | -29.33B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 311.42B KRW | KR#1,012/2,405 Sec#65/231 |
| Net Assets | 187.46B KRW | KR#987/2,405 Sec#70/231 |
| Employees | 671 | KR#373/2,405 Sec#31/231 |
| Value | ||
| P/B | 1.04x | KR#1,569/2,405 Sec#99/231 |
| P/S | 1.24x | KR#1,574/2,405 Sec#92/231 |
| Profitability | ||
| ROE | -15.64% | KR#2,024/2,405 Sec#155/231 |
| ROA | -9.42% | KR#2,081/2,405 Sec#156/231 |
| Op. Margin | -15.40% | KR#2,066/2,405 Sec#141/231 |
| Revenue Growth | 2.68% | KR#1,332/2,405 Sec#133/231 |
| Financial Health | ||
| Debt Ratio | 66.13% | KR#1,164/2,405 Sec#142/231 |
| Total Debt | 91.87B KRW | KR#758/2,405 Sec#47/231 |
| Cash | 18.36B KRW | KR#1,297/2,405 Sec#100/231 |
| Current Ratio | 1.33x | KR#1,342/2,405 Sec#143/231 |
| Performance | ||
| 1Y Return | -62.37% | KR#2,185/2,405 Sec#206/231 |
| 1M Return | -6.55% | KR#859/2,405 Sec#79/231 |
| From 52W High | -64.35% | KR#1,847/2,405 Sec#152/231 |
| 1Y MDD | -65.00% | KR#1,716/2,405 Sec#145/231 |
| Trading | ||
| Volume | 22,566 shares | KR#1,415/2,405 Sec#137/231 |
| Trading Value | 135.1M KRW | KR#1,311/2,405 Sec#144/231 |
| Foreign Own. | 7.44% | KR#599/2,405 Sec#49/231 |
| Per Share | ||
| EPS | -897 KRW | KR—/2,405 Sec—/231 |
| BPS | 5,735 KRW | KR#1,402/2,405 Sec#100/231 |
Company Info
Established in 1957, the company changed its name to Binex in 2000, listed on KOSDAQ in 2001, and expanded its business in 2015. It operates chemical pharmaceutical manufacturing and biopharmaceutical CDMO businesses, producing over 120 products in Busan and providing CDMO services in Songdo and Osong. To advance as a global CDMO, the company has passed GMP audits and plans to obtain cGMP certification and expand production capacity through an FDA audit in 2025, solidifying its standing as a global bio hub. Binex is headquartered in Saha-gu, Busan.